Journal of Experimental Hematology % - 40%
|
|
- Meredith Osborne
- 7 years ago
- Views:
Transcription
1 Journal of Experimental Hematology Article ID T CAR - T B / * B / B / CD20 B / 20% - 40% 5 B CD19 T CAR-T CD19 CAR-T B CAR-T B / CD19 CAR-T B / B T R R A doi /j. issn Clinical Translational Re se arch of Chime ric Antige n Re ce ptor-t CAR-T Cells for the Treatment of Relapsed and Refractory B-ce ll Lymphoma / Le uke mia Review YUAN Shun-Zong SU Hang * Department of Lymphoma Head and Neck Cancer Affiliated Hospital of Academy of Military Medical Sciences Beijing China * Corresponding Author SU Hang Senior Physician Associate Professor. suhang307@ 126. com Abstract B-cell lymphoma and leukemia are the most common subtypes of malignant lymphomas. Relapse and refractory to multiple therapy are the main reasons of treatment failure. As the classical anti-tumor methods surgery radiation chemotherapy and palliative therapy have cured lots of cancer patients. However each year many patients still died of different kinds of hard-to-treat cancers. Although the ratio of complete remission of B-cell lymphoma / leukemia patients particularly with CD20 positive mature B cell malignancies has been largely increased after the application of Rituximab in clinic nearly 20% - 40% patients still died due to relapse and refractory to the treatment. During last five years the development of chimeric antigen receptor-t CAR-T cells especially CD19 CAR-T cells which can recognize CD19 specifically expressed on B cells and have been demonstrated to be significantly effective to relapsed and refractory B cell lymphoma /leukemia in clinical trials has gradually attracted extensively concerning from researchers and clinicians. Many medical institutions all over the world besides in China have registered the clinical trials for B- cell lymphoma /leukemia patients by use of CAR-T cells. In this review we summarize the developmental history the main ongoing clinical trials and proved potential adverse affects of CD19 CAR-T cells for the treatment of patients with B-cell lymphoma / leukemia. Key words B-cell lymphoma leukemia chimeric antigen receptor-t cell J Exp Hematol B T NK 85% 1 WHO 90% B / *. suhang307@ 126. com
2 1138 Journal of Experimental Hematology CD20 B CAR CD3ζ / / B FcγRIIIAγ CAR-T 5 / Hwu 6-7 Stancovski 7 TNP scfv MOv18 Her2 scfv 76% 1-2 B / CAR-T MOv18 Her2 20% - 30% Zelig Eshhar CAR-T 1-2 B / 1998 Jensen 8 CD20 scfv CAR-T CD Cooper 9 CD19 scfv CD8 + CAR-T B B-ALL I 2006 Kowolik CD19 CAR-T CD28 scfv CD3ζ T 2 CAR-T Carpenito 11 CAR CD137 CAR-T 2011 Carl June T CAR-T Zhong 12 2 B 2 CAR-T B CAR-T 13 Kochenderfer / CAR-T 14 2 CAR-T IL-2 IFN-γ 3 CAR-T CAR-T 300 Carl June Michel Sadelain Steven A. Rosenberg Cooper B / CAR-T CAR-T B CAR-T B CAR-T CAR-T 1989 Gross 4 TNP 2008 Till 15 1 CD20 scfv 1 CAR-T T TCR α β CAR-T T T B 5 TNP B CD20 CAR-T 1993 TNP 2012 Till 16 scfv CD3ζ /FcγRIIIAγ 3 3 CD20 CAR-T T CTL TNP CAR-T TNP B
3 T CAR-T B / 1139 CD19 CD19 CAR-T B B-ALL / 2010 Kochenderfer CD anti-cd19 CAR-T CD19 CAR-T 32 CD Kalos 18 Porter 19 Carl June 3 CD19 CAR-T 3 B B CAR-T B-CLL Brentjens 20 Michel Sadelain B CAR-T 2 CD19 CAR-T 8 B- CLL 1 B B-ALL CAR-T 1 6 Savoldo 21 Gianpietro Dotti 2 CD19 CAR-T 5 B B CD19 CD19 CAR-T B CAR-T 2 / Brentjens h 2012 Kochenderfer 22 2 CD19 CAR-T 8 / 1 44 h 7 1 Kochenderfer B-CLL 18 d Brentjens 2 Michel Brentjens 2 Sadelain 5 B-ALL 2 CD19 CAR-T Grupp 23 Carl June 28 3 CD19 CAR-T 2 B-ALL 1 23 Davila 25 Michel Sadelain Kochenderfer 24 Steven A. Rosenberg 2 CD19 CAR- C - B T 10 B / B-CLL CAR-T Davila 25 Michel Sadelain 16 / B ALL 2 CD19 CAR-T 15 CD19 CAR-T 88% CD19 CAR-T CD19 CAR-T B / CAR-T CAR-T anti-cd19 CAR-T B CAR-T B-ALL T
4 1140 Journal of Experimental Hematology T Brentjens RJ Davila ML Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-re- Sci Transl Med mrna fractory acute lymphoblastic leukemia Rosenberg ra138. T visited. Nat Rev Drug Discov FDA T CAR-T CAR-T 33 Med receptors. J Immunol Maxcyte CAR-T mrna % 50 ml mrna cells. Cancer Res B CAR-T eradication. Mol Ther cancer therapy. Nat Rev Cancer B Immunother CAR-T 15 Till BG Jensen MC Wang J 1 Cheson BD Leonard JP. Monoclonal antibody therapy for B-cell non-hodgkin's lymphoma. N Engl J Med Lesterhuis WJ Haanen JB Punt CJ. Cancer immunotherapy re- 4 Gross G Waks T Eshhar Z. Expression of immunoglobulin-t-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA Eshhar Z Waks T Gross G et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA Hwu P Shafer GE Treisman J et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp 7 Stancovski I Schindler DG Waks T et al. Targeting of T lymphocytes to Neu / HER2-expressing cells using chimeric single chain Fv 8 Jensen M Tan G Forman S et al. CD20 is a molecular target for scfvfc zeta receptor redirected T cells implications for cellular immunotherapy of CD20 + malignancy. Biol Blood Marrow Transplant 9 Cooper LJ Topp MS Serrano LM et al. T-cell clones can be rendered specific for CD19 toward the selective augmentation of the graft-versus-b-lineage leukemia effect. Blood Kowolik CM Topp MS Gonzalez S et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T 11 Carpenito C Milone MC Hassan R et al. Control of large established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA Zhong XS Matsushita M Plotkin J et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase / AKT / Bcl-XL activation and CD8 + T cell-mediated tumor 13 Kershaw MH Westwood JA Darcy PK. Gene-engineered T cells for 14 Kochenderfer JN Feldman SA Zhao Y et al. Construction and preclinical evaluation of an anti-cd19 chimeric antigen receptor. J et al. Adoptive immunotherapy for indolent non-hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood Till BG Jensen MC Wang J et al. CD20-specific adoptive immu-
5 T CAR-T B / 1141 notherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains pilot clinical trial results Blood 17 Kochenderfer JN Wilson WH Janik JE et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood Kalos M Levine BL Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med ra Porter DL Levine BL Kalos M et al. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med Brentjens RJ Riviere I Park JH et al. Safety and persistence of a- doptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood Savoldo B Ramos CA Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest Kochenderfer JN Dudley ME Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-cd19 chimeric-antigen-receptor-transduced T cells. Blood Grupp SA Kalos M Barrett D et al. Chimeric antigen receptormodified T cells for acute lymphoid leukemia. N Engl J Med Kochenderfer JN Dudley ME Carpenter RO et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood Davila ML Riviere I Wang X et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Sci Transl Med ra Le Viseur C Hotfilder M Bomken S et al. In childhood acute lymphoblastic leukemia blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell Brentjens R Yeh R Bernal Y et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells case report of an unforeseen adverse event in a phase I clinical trial. Mol T- her Barrett DM Singh N Porter DL et al. Chimeric antigen receptor therapy for cancer. Annu Rev Med Budde LE Berger C Lin Y et al. Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma. PLoS One e Hoyos V Savoldo B Quintarelli C et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma /leukemia effects and safety. Leukemia Rosenberg SA Aebersold P Cornetta K et al. Gene transfer into humans immunotherapy of patients with advanced melanoma using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med Hoyos V Savoldo B Dotti G. Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica Singh H Figliola MJ Dawson MJ et al. Manufacture of clinicalgrade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One e Li LH Shivakumar R Feller S et al. Highly efficient large volume flow electroporation. Technol Cancer Res Treat Li L Liu LN Feller S et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther
Chimeric Antigen Receptor T Cell Therapy
Chimeric Antigen Receptor T Cell Therapy Yi Lin, MD, PhD Mayo Clinic, Rochester, MN Alliance Spring Group Meeting - May 13, 2016 Presentation Objectives l Scientific overview of chimeric antigen receptor
More informationThe immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
More informationPresenter Disclosure: Renier J. Brentjens, MD, PhD. Nothing to disclose
Presenter Disclosure: Renier J. Brentjens, MD, PhD Nothing to disclose Adoptive Therapy of Cancer with T cells Genetically Targeted to Tumor Associated Antigens through the Introduction of Chimeric Antigen
More informationCAR T cell therapy for lymphomas
CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What
More informationCAR therapy: the CD19 paradigm
Series Editor: Yiping Yang CAR therapy: the CD19 paradigm Michel Sadelain The Center for Cell Engineering, Immunology Program, Departments of Medicine and Pediatrics, Memorial Sloan Kettering Cancer Center
More informationMaking the switch to a safer CAR-T cell therapy
Making the switch to a safer CAR-T cell therapy HaemaLogiX 2015 Technical Journal Club May 24 th 2016 Christina Müller - chimeric antigen receptor = CAR - CAR T cells are generated by lentiviral transduction
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationWhat is non-hodgkin lymphoma, how is it treated, and what is the unmet need?
What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationChimeric Antigen Receptor T-cell therapy for CD19+ Maligancies
Chimeric Antigen Receptor T-cell therapy for CD19+ Maligancies Noelle Frey, MD, MSCE Assistant Professor of Medicine Associate Director, Blood and Marrow Transplantation University of Pennsylvania Medical
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationProject Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D
Phase I study using T cells expressing a CD123-specific chimeric antigen receptor and truncated EGFR for patients with relapsed or refractory acute myeloid leukemia Project Lead: Stephen Forman, M.D. PI:
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationCIRM Webinar: CAR-T Cell Immunotherapy - Challenges and Opportunities Using Mature or Stem Memory T Cells, March 18th, 2015 Margo R Roberts, Ph.D.
CIRM Webinar: CAR-T Cell Immunotherapy - Challenges and Opportunities Using Mature or Stem Memory T Cells, March 18th, 2015 Margo R Roberts, Ph.D. Forward Looking Statements / Safe Harbor To the extent
More informationSommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression
More informationA disease and antibody biology approach to antibody drug discovery
A disease and antibody biology approach to antibody drug discovery Björn Frendéus, PhD VP, Preclinical research Presenter: Björn Frendéus Date: 2011-11-08 1 Antibodies have revolutionized Cancer Treatment!
More informationCancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview
Brochure More information from http://www.researchandmarkets.com/reports/3066973/ Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview Description:
More informationThe use of monoclonal antibodies in the setting of HSCT
The use of monoclonal antibodies in the setting of HSCT S Montoto, Barts Cancer Institute, London, UK Geneva 3/April/2012 www.ebmt.org Some definitions of interest: Ab and Ag Antibody (Ab)=Immunoglobulin
More informationAre CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
More informationThis presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking
Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationMALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
More informationGuidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre
Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection
More informationspecific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
More informationCytoreductive Therapy for Autologous Cell Therapy in HIV
Cytoreductive Therapy for Autologous Cell Therapy in HIV Ronald Mitsuyasu, MD Professor of Medicine UCLA Center for Clinical AIDS Research and Education (CARE Center) HSC Transfer from CCR5-delta 32 Donor
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationLeukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
More informationMEDICAL BREAKTHROUGHS RESEARCH SUMMARY
MEDICAL BREAKTHROUGHS RESEARCH SUMMARY TOPIC: Training the Body to Fight Melanoma REPORT: 3823 BACKGROUND: Melanoma is the most dangerous form of skin cancer that can be hard to treat and fatal if not
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor
More informationLymphoma Diagnosis and Classification
Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various
More informationOncology Best Practice Documentation
Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings
More informationImmune Checkpoint Blockade in Acute Myeloid Leukemia. Kinsey McCormick Hematology Fellow s Conference January 10, 2014
Immune Checkpoint Blockade in Acute Myeloid Leukemia Kinsey McCormick Hematology Fellow s Conference January 10, 2014 Overview Overview of immune checkpoints Immune checkpoints as mechanism of immune evasion
More informationPredictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University
Predictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University Changing Paradigms in Cancer Treatment Potential Uses of Biomarkers Adverse event
More informationT Cell Immunotherapy for Cancer
T Cell Immunotherapy for Cancer Chimeric Antigen Receptors Targeting Tag-72 Glycoprotein for Colorectal Cancer Mitchell H. Finer Ph.D Genetix Pharmaceuticals Inc Work Completed at Cell Genesys Inc T Cell
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationNon-Hodgkin s Lymphoma
Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationChronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.
Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates
More informationBottle-neck Problems of Current Human Cancer Therapy
International Conference on Human Cell, Tissue-based Products and Tissue Banks, Oct. 13-14,Taipei, Taiwan Autologous Dendritic Cell-based Immunotherapy of Glioblastoma Multiforme: Post-Phase-I Clinical
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationCHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
More informationNews. The Blood and Marrow Transplant Program at Northside Hospital. New Clinical Trial Assesses Use of CTLA-4 Blockade with Ipilimumab IN THIS ISSUE:
IN THIS ISSUE: Winter 2014 www.bmtga.com www.northside.com The Blood and Marrow Transplant Program at Northside Hospital News New Clinical Trial Assesses Use of Ipilimumab Page 1 NSH-BMT, Leukemia & Lymphoma
More informationTherapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma
a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University
More informationBioinformatics for cancer immunology and immunotherapy
Bioinformatics for cancer immunology and immunotherapy Zlatko Trajanoski Biocenter, Division for Bioinformatics Innsbruck Medical University Innrain 80, 6020 Innsbruck, Austria Email: zlatko.trajanoski@i-med.ac.at
More informationCancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important
More informationIncrease of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
Köhnke et al. Journal of Hematology & Oncology (2015) 8:111 DOI 10.1186/s13045-015-0213-6 JOURNAL OF HEMATOLOGY & ONCOLOGY CASE REPORT Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant
More informationGoing viral: chimeric antigen receptor T-cell therapy for hematological malignancies
Saar Gill Carl H. June Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies Authors addresses Saar Gill 1, Carl H. June 2 1 Abramson Cancer Center, Division of Hematology/
More informationFetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients
Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant Recipients Filippo Milano, 1 J. Lee Nelson, 1, 2 Colleen Delaney 1,3 1 Clinical Research Division, Fred Hutchinson Cancer Research
More informationLeukemia, Lymphoma, and Multiple Myeloma: Toward a New Understanding
Leukemia, Lymphoma, and Multiple Myeloma: Toward a New Understanding Statement of Richard Klausner, M.D. Director National Cancer Institute National Institutes of Health Department of Health and Human
More informationTwo Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Yoichi Kitamura, MD Kazuhiko Hayashi, MD Kazumi Uchida,
More informationThis report focuses on the rising potential for the newest and most promising of cancer treatments:
1 Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies Allan B. Haberman. Ph.D. This report focuses on the rising potential for the newest and most promising
More informationEquity markets Major advances in cancer therapeutics 18 August 2015
Major advances in cancer therapeutics 18 August 2015 CIO WM Research Jerome Brimeyer, Equity Sector Strategist, jerome.brimeyer@ubs.com Our cancer therapeutics investment theme recommends companies that
More informationA clinical study of cytokine-induced killer cells for the treatment of refractory lymphoma
ONCOLOGY LETTERS 2: 531-536, 2011 A clinical study of cytokine-induced killer cells for the treatment of refractory lymphoma ZHI GUO *, HAO LIU *, XUE-PENG HE, XIAO-HUA TAN, YAN ZHOU, XIA CHEN, YU-JIE
More informationT-Cell Immunotherapy Market, 2015-2030
Product Sheet More information at http://www.biomarketgroup.com/market-research-report/t-cell-immunotherapy-market-2015-2030.html T-Cell Immunotherapy Market, 2015-2030 Published: 2015-OCT-13 Pages: 419
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationFuture Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
More informationChimeric Antigen Receptor (CAR) T cell Therapy for B cell Cancers
Chimeric Antigen Receptor (CAR) T cell Therapy for B cell Cancers 13 th International Congress on Targeted Anticancer Therapies (TAT) Paris France March 2, 2015 Renier Brentjens MD PhD Associate Member
More informationLYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
More informationCD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,
More informationAbout B Cell Lymphomas Groupmeeting Klipp/Spang, December 09 2002 Dennis Kostka Max-Planck-Institute for Molecular Genetics Computational Molecular Biology Berlin 1 Overview Short History of Lymphoma Classification
More informationT Cell Maturation,Activation and Differentiation
T Cell Maturation,Activation and Differentiation Positive Selection- In thymus, permits survival of only those T cells whose TCRs recognize self- MHC molecules (self-mhc restriction) Negative Selection-
More informationChallenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute
Challenges of Hematopoietic Stem Cell Transplantation Robert J. Soiffer, MD Dana Farber Cancer Institute Hematopoietic Stem Cell Transplantation Objectives Deliver sufficient chemo-radio therapy to destroy
More informationAnti-HCV therapy in HCV-related NHL
Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral
More informationInteresting Case Series. Periorbital Richter Syndrome
Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,
More informationMultiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
Microenvironment and Immunology Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor Cancer Research Yangbing Zhao
More informationTarget discovery for T cell therapy: next steps to advance Immunotherapies
Bot et al. Journal for ImmunoTherapy of Cancer (2015) 3:31 DOI 10.1186/s40425-015-0061-5 MEETING REPORT Open Access Target discovery for T cell therapy: next steps to advance Immunotherapies Adrian Bot
More informationShantaram S. Joshi, Ph.D.
Shantaram S. Joshi, Ph.D. Functional Genomics of Leukemia Dendritic Cell Based Therapy for Cancer Dept. of Genetics, Cell Biology and Anatomy University of Nebraska Medical Center Omaha, Nebraska 68198-6395
More information2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders
UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationFDA Perspective on the Regulation of TCR/CAR T-cell Products
FDA Perspective on the Regulation of TCR/CAR T-cell Products Raj K. Puri, M.D., Ph.D. Director, Division of Cellular and Gene Therapies, FDA, CBER CIMT2014 Talk (by Phone) Date: May 8, 2014 Time: 12:30
More informationAcute myeloid leukemia (AML)
Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult
More informationPerspectives on HCT Program Challenges in a Changing Reimbursement Environment The good, the bad, and the ugly
Perspectives on HCT Program Challenges in a Changing Reimbursement Environment The good, the bad, and the ugly Richard T Maziarz, MD Oregon Health & Science Univ February 27, 2014 THE GOOD Provider Principles
More informationBreakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation May 2015
Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation May 2015 Forward-looking statements / safe harbor This presentation and the accompanying oral
More informationHairy Cell Leukemia Facts
No. 16 in a series providing the latest information for patients, caregivers and healthcare professionals www.lls.org Information Specialist: 800.955.4572 Highlights l Hairy cell leukemia (HCL) is a chronic
More informationDESCRIPTION/BACKGROUND
Original Issue Date (Created): August 23, 2004 Most Recent Review Date (Revised): Effective Date: October 21, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND Hematopoietic Stem-Cell Transplantation
More informationThe Need for a PARP in vivo Pharmacodynamic Assay
The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235
More informationB Cells and Antibodies
B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production
More informationLymphomas after organ transplantation
Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative
More informationWhat is a Stem Cell Transplantation?
What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am
More informationOKT3. ~ The first mouse monoclonal antibody. used in clinical practice in the field of transplantation ~
g944202 潘 怡 心 OKT3 ~ The first mouse monoclonal antibody used in clinical practice in the field of transplantation ~ As everybody knows, OKT3 is the first mouse monoclonal antibody produced for the treatment
More informationEU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com
EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com Investor Relations: Stan Panasewicz Phone: +1 732-524-2524 Louise Mehrotra Phone:
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationChemoimmunotherapy resistant follicular lymphoma A single institutional study
Cancer Research Journal 2014; 2(5): 93-97 Published online September 30, 2014 (http://www.sciencepublishinggroup.com/j/crj) doi: 10.11648/j.crj.20140205.13 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online)
More informationImmune Therapy for Pancreatic Cancer
Immune Therapy for Pancreatic Cancer December 16, 2014 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only:
More informationMEDICAL POLICY POLICY TITLE
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): Effective Date: April 15, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND High dose chemotherapy (HDC) involves the administration
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationCancer Immunotherapy Research. Selected publications featuring next-generation sequencing technology
Cancer Immunotherapy Research TABLE OF CONTENTS 04 Introduction 06 Vaccine immunotherapy 08 Adoptive cell transfer Chimeric antigen receptor (CAR) T cells Tumor infiltrating lymphocytes (TILs) 14 Checkpoint
More information2) Macrophages function to engulf and present antigen to other immune cells.
Immunology The immune system has specificity and memory. It specifically recognizes different antigens and has memory for these same antigens the next time they are encountered. The Cellular Components
More informationisbtc/sitc Exceptional Service Award Recipients
isbtc/sitc Exceptional Service Award Recipients Awarded October 3, 2010 for distinguished leadership, continued contribution, and consummate dedication which fostered the growth and success of isbtc. Michael
More informationServier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies
PRESS RELEASE Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies Servier Also Enters Into Exclusive Global
More informationI was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several
Track 3: Goals of therapy I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several factors she ll use to decide what s best for me. Let s talk about making treatment
More informationMicrobiology AN INTRODUCTION EIGHTH EDITION
TORTORA FUNKE CASE Microbiology AN INTRODUCTION EIGHTH EDITION Differentiate between innate and acquired immunity. Chapter 17 Specific Defenses of the Host: The Immune Response B.E Pruitt & Jane J. Stein
More informationKITE PHARMA, INC. FORM 424B1. (Prospectus filed pursuant to Rule 424(b)(1)) Filed 12/12/14
KITE PHARMA, INC. FORM 424B1 (Prospectus filed pursuant to Rule 424(b)(1)) Filed 12/12/14 Address 2225 COLORADO AVENUE SANTA MONICA, CA 90404 Telephone (310) 824-9999 CIK 0001510580 Symbol KITE SIC Code
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationAdvances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope
Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University
More informationCancer and the immune system: can we beat cancer at its own game?
Cancer and the immune system: can we beat cancer at its own game? Andrew R. Haas, MD, PhD Assistant Professor of Medicine University of Pennsylvania Medical Center Philadelphia, Pa Why can t immune
More information